Brought to you by 
Bayer HealthCare to sell Nuvelo's blood clotting agent; ends
16 Jun 2021
Executive Summary
Nuvelo (develops cardiovascular and cancer candidates) licensed Bayer HealthCare exclusive rights to market its Phase III thrombolytic alfimeprase outside of the US. Nuvelo retains exclusive US development and commercialization rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer HealthCare to sell Nuvelo's blood clotting agent; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice